Lantern Pharma Inc.

Aug 14, 2026

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Lantern Pharma has released its financial results for the second quarter of 2026, alongside a business update. The report highlights the company's performance and strategic direction. Further details on financial metrics and future plans were not provided in the article.

Aug 7, 2026

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET

Lantern Pharma has announced that it will report its operating and financial results for the second quarter of 2026. The report is scheduled for August 14th, 2026, at 9:00 a.m. ET. This update is part of the company's regular financial reporting process.

Aug 3, 2026

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

Lantern Pharma has announced the establishment of Open Medicine AI as a separate company. This new entity aims to commercialize and enhance its Multi-Agent AI Co-Scientist Platform, which is designed to transform the field of medicine. The initiative reflects Lantern Pharma's commitment to innovation in healthcare technology.

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

Lantern Pharma has received clearance from the European Medicines Agency (EMA) to advance its Phase 1b/2 clinical trial for LP-184, also known as Zirdafulven, targeting biomarker-selected advanced bladder cancer. This development highlights the company's commitment to developing innovative therapies for this challenging condition. The trial aims to assess the efficacy and safety of LP-184 in this specific patient population.

Jul 23, 2026

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

Lantern Pharma has received a Notice of Allowance from the USPTO for its patent application concerning biomarker-guided treatment methods for solid tumor cancers. This patent will enhance the company's ability to develop targeted therapies using its AI and genomic data capabilities. The allowed claims specifically focus on methods for selecting and treating patients with various solid tumors.

Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer

Lantern Pharma has launched ZetaOmics, an autonomous computational biology module designed to enhance bioinformatics and multi-omic analysis for all cancer types. This innovative tool is particularly focused on addressing the needs of rare and pediatric cancers. The introduction of ZetaOmics marks a significant advancement in the company's AI-driven precision oncology efforts.

Jun 2, 2026

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

Lantern Pharma reported promising data from its Phase 2 HARMONIC™ trial for LP-300 in patients with EGFR Exon 21 L858R-mutant NSCLC. The trial indicates that progression-free survival improves with longer treatment durations, with a median PFS of 8.9 months for patients receiving up to six cycles. The safety profile remains favorable, supporting an extension of treatment cycles from six to eight.

May 19, 2026

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

Lantern Pharma has announced a successful outcome from its FDA Type C meeting regarding the HARMONIC™ Phase 2 trial of LP-300. This trial specifically targets never-smokers diagnosed with non-small cell lung cancer (NSCLC). The positive feedback from the FDA is a significant step forward for the company's development plans.

May 15, 2026

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates Disciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-A

Lantern Pharma reported a 27% reduction in net loss year-over-year for Q1 2026 and emphasized capital-efficient operations. The company advanced multiple clinical programs, including successful FDA interactions, while simultaneously launching its AI platform, withZeta.ai. Financially, Lantern strengthened its balance sheet with $9.25 million in financing and plans to create a separate entity for its AI assets. The HARMONIC trial for LP-300 is ongoing, targeting specific patient populations in multiple countries and has shown promising early safety data.

May 14, 2026

▲ +24.7%on this newsshared move

Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor $4.4 million upfront with up to an additional $4.85 million of potential aggregate gr

Lantern Pharma Inc. announced a registered direct offering that could raise up to $9.25 million, which includes a $4.4 million upfront payment and potential additional funds through the exercise of warrants. Concurrently, the company plans to establish a separate business entity focused on its AI platform, aimed at enhancing its fundraising efforts. The closing of the offering is expected around May 14, 2026, pending customary conditions. Investors have expressed optimism regarding the company's AI capabilities, though there are risks related to the exercise of warrants and the success of product development.

May 12, 2026

Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

Lantern Pharma Inc. will report its first quarter 2026 operating and financial results on May 15, 2026. The report will include financial results for the quarter ending March 31, 2026, along with updates on clinical trials and the development of the company's AI platforms. Lantern Pharma focuses on precision oncology therapies using AI and machine learning.

May 7, 2026

Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™

Lantern Pharma has announced a new development roadmap for its withZeta.ai platform, which is designed to enhance oncology research and drug discovery through AI. The roadmap includes the introduction of two major components: ZetaSwarm™, a multi-agent swarm intelligence layer, and ZetaOmics™, a computational biology toolkit. These advancements aim to improve the efficiency and effectiveness of drug discovery processes.

Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally

Lantern Pharma has announced the evolution of its predictBBB.ai platform into a Large Quantitative Model (LQM), providing real-time molecular intelligence accessible via a web interface. This advancement enables pharmaceutical scientists and medicinal chemists to enhance their drug development processes. The LQM aims to improve precision oncology efforts globally.

Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity

Lantern Pharma's investigational drug LP-300 has shown promising results, demonstrating an 8.3-month median progression-free survival in patients with EGFR L858R lung cancer after failure of targeted therapy. Notably, the treatment did not introduce any additional toxicity, suggesting a favorable safety profile. This emerging data could represent a significant advancement in the treatment of this specific lung cancer type.

Apr 14, 2026

Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22

Lantern Pharma has launched withZeta.ai, an innovative multi-agentic AI co-scientist aimed at advancing drug discovery and development for rare cancers. Subscriptions for the platform are now open, with debut events scheduled at Nasdaq MarketSite on April 16 and at AACR 2026 from April 17 to April 22. This launch represents a significant step forward in leveraging AI technology within the biopharma sector.

Mar 30, 2026

▲ +10.3%on this news· ran to +45% by day 3

Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates Year of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization

Lantern Pharma Inc. announced its fourth quarter and full year 2025 financial results, highlighting significant operational achievements and advancements in its clinical pipeline. The company achieved clinical validations and received FDA IND clearance for its pediatric CNS cancer trial. Despite positive developments, there are regulatory challenges ahead, particularly concerning proposed amendments to its ongoing HARMONIC trial. Lantern is also expanding its AI capabilities with the launch of an AI Center of Excellence in India.

Mar 27, 2026

▼ -46.4%on this newsshared move

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

Lantern Pharma and Starlight Therapeutics have received FDA clearance for an Investigational New Drug application for STAR-001, a precision oncology compound. The planned Phase 1 trial will evaluate STAR-001 as a monotherapy and in combination with spironolactone for pediatric patients with relapsed or refractory CNS malignancies. This trial aims to address the significant unmet medical need in pediatric neuro-oncology, particularly for aggressive CNS tumors.

Mar 24, 2026

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

Lantern Pharma Inc. will host a webcast on March 30, 2026, to discuss its fourth quarter and fiscal year 2025 financial results. CEO Panna Sharma will lead the discussion, which will cover operational performance and future milestones in the development of its AI platform, RADR®. The company emphasizes its focus on cancer therapies and the importance of investor engagement.

Feb 11, 2026

Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026

Lantern Pharma Inc. will present at the 7th Glioblastoma Drug Development Summit in Boston from February 17-19, 2026. CEO Panna Sharma will discuss the application of their AI platform, RADR®, in addressing challenges in treating aggressive brain cancers. The company is focused on developing therapies for CNS cancers, including recurrent glioblastoma.

Jan 20, 2026

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Lantern Pharma has received FDA Orphan Drug Designation for LP-284, aimed at treating soft tissue sarcomas. This designation adds to its previous approvals for hematologic malignancies, highlighting LP-284's potential in solid tumors. The drug targets DNA repair deficiencies, addressing a significant unmet need in adult oncology, particularly for patients with limited treatment options.

Jan 20, 2026

Lantern Pharma’s LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Lantern Pharma's LP-284 has received FDA Orphan Drug Designation for treating soft tissue sarcomas, marking its third such designation. This expands the drug's potential beyond hematologic malignancies into solid tumors, addressing a significant unmet need in adult patients. The designation highlights the drug's synthetic lethal mechanism targeting DNA repair deficiencies, which aligns with the characteristics of adult soft tissue sarcomas.

Nov 13, 2025

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Laun

Lantern Pharma has reported strong third-quarter results for 2025, highlighting significant milestones in their clinical program and regulatory advancements. Their LP-184 Phase 1a trial has achieved all primary endpoints, showing a 48% clinical benefit rate among cancer patients with specific mutations. Additionally, a recent FDA Type C meeting affirmed the clinical trial design for a pediatric CNS cancer program while confirming a combination treatment strategy. The company demonstrated continued momentum in their AI-driven platform, further positioning themselves for growth in oncology markets.

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates Major milestone achieved with successful completion of enrollment for LP-184 Phase 1a clinical trial , with 65 patients enrolled across a

Lantern Pharma reported its second quarter 2025 financial results, highlighting major advancements in its clinical trials. Successful enrollment of 65 patients in the LP-184 Phase 1a trial was achieved, paving the way for further Phase 1b/2 studies targeting recurrent triple negative breast cancer and bladder cancer. The company also reported complete responses in patients from its HARMONIC trial, indicating the efficacy of its drug candidates. Additionally, Lantern maintains strong financial stability, essential for continuing its operational and clinical advancements.

May 15, 2025

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025 . A

Lantern Pharma Inc. (LTRN) announced its first quarter 2025 financial results, stating the completion of LP-184 Phase 1a clinical trial enrollment, expected by June 2025. The company also reported positive early data from ongoing trials, notably for LP-300 in never-smokers with NSCLC. Lantern emphasized advancements in its AI-driven RADR platform and financial stability with significant cash reserves. Additionally, Future clinical trials are planned for LP-184 in various cancer indications, showing a commitment to addressing unmet patient needs.

Mar 27, 2025

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results HARMONIC trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker N

Lantern Pharma reported strong financial results for Q4 and year-end 2024, alongside significant updates on its drug development pipeline. The HARMONIC trial for LP-300 demonstrated an 86% clinical benefit rate and a 43% objective response rate in never-smoker NSCLC patients. The company obtained FDA Fast Track Designations for LP-184, enhancing its market potential in cancers with high unmet need. Furthermore, the RADR AI platform continues to advance precision oncology, showcasing the company’s commitment to utilizing technology in drug development.

Nov 7, 2024

LTRNClinical Trials

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating add

Lantern Pharma Inc. reported its third quarter 2024 financial results, highlighting advancements in its AI-guided oncology pipeline. Key updates include promising progress in the Harmonic trial for LP-300 and the Fast Track Designation for LP-184 in glioblastoma. The company aims to leverage its RADR AI platform to develop targeted cancer therapies more efficiently. Lantern is also strategically expanding its clinical trials into Asian markets to target specific patient populations.

Aug 8, 2024

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates Active clinical trials across three AI-guided drug candidates with additional ADC-based preclinical molecules in evaluation for developmen

Lantern Pharma reported significant developments during the second quarter of 2024, including an 86% clinical benefit rate from the LP-300 trial's initial patient cohort. The company also received a patent for its drug candidate LP-284 and continues to advance Phase 1 clinical trials for LP-184 and LP-284 without dose-limiting toxicities. Despite a decrease in cash reserves and a net loss of approximately $4.96 million, Lantern initiated a collaboration with Oregon Therapeutics to expedite the development of a new drug candidate. New diagnostic tools for LP-184 are expected to enhance patient selection in future oncology trials.

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second

Lantern Pharma Inc. reported its financial results for the first quarter of 2024, highlighting advancements in multiple clinical trials and the progress of its AI platform. The company aims for data readouts for its drug candidate, LP-184, by late summer or early fall, particularly focusing on DDR deficient tumors. Despite the positive operational progress, Lantern posted a net loss of approximately $5.4 million, reflecting increased R&D expenses driven by trial activities. Overall, the market potential for their drug candidates remains substantial, fueling optimism for future developments.

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights Multiple clinical trials across three AI-guided drug candidates are active with first expected data and readouts for LP-1

Lantern Pharma (NASDAQ: LTRN) announced its financial results for the fourth quarter and fiscal year 2023, highlighting significant progress in its oncology drug development programs. The company is actively conducting multiple clinical trials across three AI-guided drug candidates, with initial data expected for LP-184 in late 2024. Lantern has achieved substantial growth in its proprietary RADR AI platform, exceeding its 2023 goals for data points and setting ambitious targets for 2024. The firm's expansion into international markets for its clinical trials and the establishment of a subsidiary focused on CNS cancers demonstrate its commitment to innovative cancer therapies.

Nov 8, 2023

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights Received IND clearance from FDA to initiate Phase 1 clinical trial for LP-284 , a first-in-human trial for advanced, refractory non-H

Lantern Pharma (NASDAQ: LTRN) announced its third quarter 2023 financial results, highlighting significant operational achievements, including FDA clearance to initiate a Phase 1 clinical trial for LP-284, aimed at treating advanced non-Hodgkin's lymphomas. The company also dosed its first patient in a Phase 1 trial for LP-184, targeting various advanced solid tumors. Lantern is expanding its Phase 2 LP-300 trial to East Asian countries, where a notable portion of lung cancer cases arise in never-smokers. With a strong cash position, Lantern aims to maintain progress in its clinical programs and leverage its AI platform, RADR, for future developments.

Aug 9, 2023

Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights Obtained FDA clearance of the IND application for LP-184 and activated initial clinical sites for the Phase 1 basket trial in relaps

Lantern Pharma reported strong operational highlights and financial results for Q2 2023, marked by the FDA's clearance of the IND application for LP-184 and the activation of clinical sites for a Phase 1 trial. The company has made significant advancements in its drug pipeline, including IND-enabling studies for LP-284 expected to be submitted in August and ongoing recruitment for the Phase 2 Harmonic trial in NSCLC. Lantern's RADR platform continues to evolve, aiming to transform oncology drug development with AI-driven insights and collaborations, including an initiative with Bielefeld University focused on antibody drug conjugates.

Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights Dosed first patient in the Phase 2 Harmonic clinical trial; a study for the unique population of non-small lung cancer patients who a

Lantern Pharma reported its first quarter 2023 financial results and announced key operational milestones. The company successfully dosed its first patient in the Phase 2 Harmonic clinical trial for non-small cell lung cancer targeting never-smokers. Additionally, Lantern anticipates submitting an IND application for LP-184 to the FDA and aims to launch Phase 1 trials for two new drug candidates in 2023. The company continues to leverage its AI platform RADR to streamline drug development and improve the speed and cost of bringing therapies to market.

Mar 20, 2023

Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights The Harmonic clinical trial, a Phase 2 study in never-smoker patients with non-small lung cancer, has activated 5 cl

Lantern Pharma has reported positive operational highlights and financial results for Q4 and fiscal year 2022. The company has activated five clinical trial sites for its Harmonic clinical trial targeting never-smokers with non-small cell lung cancer, with first patient enrollment expected in Q2 2023. Lantern also plans to submit IND applications for LP-184 and LP-284 in mid-2023, with the latter receiving Orphan Drug Designation for treating mantle cell lymphoma. The firm possesses a strong cash position, with projections extending into 2025, and aims to leverage AI technologies for oncology drug development.

Dec 2, 2022

Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET

DALLAS, Dec. 02, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Lantern Pharma Inc (Nasdaq: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timelin

Nov 7, 2022

Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights The Harmonic clinical trial activated the first two clinical trial sites for a Phase 2 study in never-smoker patients with non-small

Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights The Harmonic clinical trial activated the first two clinical trial sites for a Phase 2 study in never-smoker patients with non-small lung cancer and anticipates multiple additional sites in the US d

Aug 8, 2022

Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights Lantern has launched the Phase 2 clinical trial, Harmonic , for LP-300. The Harmonic clinical trial is focused on never smokers with

Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights Lantern has launched the Phase 2 clinical trial, Harmonic , for LP-300. The Harmonic clinical trial is focused on never smokers with advanced non-small cell lung cancer (NSCLC) and will begin patie

Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights RADR , Lantern's proprietary A.I. and machine learning platform, has now surpassed 20 billion data points, enhancing its precision, i

Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") and machine learning (ML) platform

Apr 26, 2022

Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors DALLAS

Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors DALLAS, April 26, 2022/PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial

Mar 22, 2022

Lantern Pharma Announces Extension of Existing Share Repurchase Program DALLAS

Lantern Pharma Announces Extension of Existing Share Repurchase Program 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") and machine learning (ML) platform to transfo

Mar 10, 2022

Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights RADR , Lantern's proprietary A.I. and machine learning platform, grew from 1.2 billion to over 18 billion data point

Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights March 10, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") and machine

Jan 24, 2022

Lantern Pharma Receives Rare Pediatric Disease and Orphan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervou

Lantern Pharma Receives Rare Pediatric Disease and Orphan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System DALLAS, January 24, 2022 /PRNewswire/ -- Lantern

Nov 22, 2021

Lantern Pharma Announces Share Repurchase Program DALLAS

Pharma Announces Share Repurchase Program DALLAS, November 22, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern" or the "Company"), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transform the

Nov 1, 2021

Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights - RADR A.I. platform surpasses 10 billion datapoints, significantly enhancing speed and scope of new drug development and expanding pot

Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights DALLAS, November 1, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to tran

Jul 29, 2021

Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights Obtained positive preclinical data in pancreatic cancer showing a significant reduction, averaging 93%, in tumor volume in in-vivo a

Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights DALLAS, TX - July 29, 2021 - Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern"), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform

May 3, 2021

Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights RADR A.I. platform surpasses 4.6 billion datapoints curated for oncology drug development across a wide a range of tumors and drug cl

Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights DALLAS, TX - May 3, 2021 - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transform o

Mar 10, 2021

Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights RADR artificial intelligence ("A.I.") platform surpassed 1.2 billion datapoints Advanced opportunities for LP-184 in gl

Lantern Pharma Reports Fourth Quarter and Financial Results and Operational Highlights DALLAS, TX - March 10, 2021 - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transfor

Oct 29, 2020

Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress Surpassed One Billion Curated Data Points Powering Company's Proprietary A.I. Platform, RADR , for Cancer Drug Development Adva

Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress DALLAS, TX - October 29, 2020 - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary artificial intelligence ("A.I.") platform, RADR , to transf

Aug 21, 2020

AMENDED AND RESTATED LANTERN PHARMA INC. 2018 EQUITY INCENTIVE PLAN I. GENERAL PROVISIONS 1.1 Establishment . On

AMENDED AND RESTATED LANTERN PHARMA INC. 2018 EQUITY INCENTIVE PLAN Establishment. On August 29, 2018, the Board of Directors of Lantern Pharma Inc. adopted the Lantern Pharma Inc. 2018 Equity Incentive Plan. The Lantern Pharma Inc. 2018 Equity Incentive Plan was approved by t

Jul 30, 2020

Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress Closed Initial Public Offering Raising Gross Proceeds of $26.3 Million Surpassed 500 Million Curated Oncology Data Points for

Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress Initial Public Offering Raising Gross Proceeds of $26.3 Million 500 Million Curated Oncology Data Points for Company's RADR A.I. Platform Manufacturing Capabilities for LP-300 and LP-184 Tria

Jun 29, 2020

Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR , Surpasses 450 Million Data Points, Ahead of Schedule, and Accelerates the Company’s Path to 1 Billion Data Points Curated Specifically for Oncology Drug Development and Drug Response Prediction

The machine learning-powered RADR® platform identifies genomically distinct cancer subtypes, and patient groups, that can respond to specific drugs that Lantern and its partners are developing The growing A.I. platform will be pivotal in uncovering combination therapies using La

Jun 17, 2020

Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting

DALLAS, June 17, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that w

Jun 15, 2020

Lantern Pharma Announces Closing of Initial Public Offering

DALLAS, June 15, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma Inc. (LTRN) (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the p

Jun 15, 2020

Monday

Monday, June 15, 2020 Lantern Pharma Announces Closing of Initial Public Offering DALLAS, TX / June 15, 2020 / Lantern Pharma Inc. (LTRN) (the "Company"), a clinical stage biotechnology company, focused on leveraging artificial intelligence ("A.I."), machine learning and gen

Jun 10, 2020

Lantern Pharma Announces Pricing of Initial Public Offering

DALLAS, June 10, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma Inc. (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients

Dec 17, 2019

Lantern Pharma Appoints David Margrave as Chief Financial Officer and Kishor Bhatia, Ph.D., as Chief Scientific Officer

DALLAS and KEARNY, N.J., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, announced today the appointment of David Margrave as Chief Financial Officer and Kishor Gopaldas Bhatia, Ph.D., as Chief Scientific Officer. Co

Dec 11, 2019

Lantern Pharma Expands and Strengthens Board of Directors with Healthcare and Pharma Industry Veterans Franklyn Prendergast, MD, Ph.D. and Vijay Chandru, Ph.D.

DALLAS and KEARNY, N.J., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, announced today the appointment of two new members, Franklyn Prendergast, MD, Ph.D. and Vijay Chandru, Ph.D. to its board of directors. In addi

Nov 7, 2019

Lantern Pharma CEO Panna Sharma to Present & Participate in Panel Discussion at AI Applications in Biopharma Summit 2019 in Boston

DALLAS and KEARNY, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI, machine learning (ML) and genomics, today announced its Chief Executive Officer, Panna Sharma, will serve as a speaker and panel participant at the upcoming

Oct 29, 2019

Lantern Pharma Selects Reprocell Inc. to Provide Preclinical Screening and Biomarker Discovery Services for Portfolio of Targeted Oncology Drugs

DALLAS and KEARNY, N.J., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging A.I., machine learning (ML) and genomics, announced today that it has selected Reprocell to provide preclinical screening and drug sensitivity work for its port

Oct 7, 2019

Lantern Pharma CEO Panna Sharma to Speak at Bio Data World West 2019

DALLAS and KEARNY, N.J., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, today announced its Chief Executive Officer, Panna Sharma, will present at the 3rd Annual Bio Data World West 2019 in San Diego, CA. Sharma wi

Oct 1, 2019

Lantern Pharma and National Cancer Institute Partner to Aid Precision Oncology Research and Treatments

DALLAS and KEARNY, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Lantern Pharma, a clinical stage oncology biotech leveraging AI and genomics, today announced a collaboration agreement with the Developmental Therapeutics Branch (DTB) of the National Cancer Institute (NCI) to identify g

Sep 18, 2019